{"id":5282,"date":"2023-08-01T08:16:33","date_gmt":"2023-08-01T08:16:33","guid":{"rendered":"https:\/\/wapcpharm.org\/journal\/?p=5282"},"modified":"2023-08-08T08:28:04","modified_gmt":"2023-08-08T08:28:04","slug":"west-african-journal-of-pharmacy-2012-23-2-51-57","status":"publish","type":"post","link":"https:\/\/wapcpharm.org\/journal\/west-african-journal-of-pharmacy-2012-23-2-51-57\/","title":{"rendered":"West African Journal of Pharmacy (2012) 23 (2) 51 \u2013 57"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Invitro activity of gemifloxacin against some clinical bacterial isolates\u00a0<\/b>of urinary tract infections<\/b><\/p>

\u00a0<\/p>

Ching, Fidelis Poh* , Josephs, Godwin Chimechefulam and Ossai, Awele Maureen<\/p>

\u00a0<\/p>

*1 Department of Pharmacology, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta\u00a0University, Wilberforce Island, Yenagoa, Bayelsa State, Nigeria. E-mail: fidelching@yahoo.ca<\/span><\/p>

\u00a0<\/p>

2\u00a0Department of Pharmaceutical Microbiology, Faculty of Pharmacy,\u00a0<\/span>University of Benin, Benin City, Edo\u00a0<\/span>State, Nigeria E-mail:godwinjosephs@yahoo.com<\/span><\/p>

\u00a0<\/span><\/p>

Corresponding author: Dr Ching, Fidelis Poh<\/p>

E-mail: fidelching@yahoo.com, Phone: +2348067541738<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

ABSTRACT<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Background: <\/b>Gemifloxacin is a third generation fluoroquinolone with broad spectrum antimicrobial and enhanced activity against both aerobic and anaerobic Gram positive bacteria. It is recommended for the <\/span>treatment of respiratory tract infections.<\/span><\/p>

Objectives<\/b>: This study evaluated and compared the antibacterial activity of gemifloxacin with ciprofloxacin, ofloxacin and norfloxacin using minimum inhibition concentration assays against Staphylococcus aureus, <\/span>Escherichia coli, Alcaligenes faecalis, Pseudomonas aeruginosa, Serratia marcescens, Enterobacter <\/span>aerogenes, Proteus vulgaris and Klebseilla pneumoniae obtained from urine samples of patients.<\/span><\/p>

Methods:<\/b> The minimum inhibition concentration (MIC) evaluations were employed for the comparative studies and zones of inhibition assay were further used to determine the antibacterial activity of <\/span>gemifloxacin. For the MIC evaluations, final nutrient agar concentrations of 5, 7.5, 10, 15, 20, 25 and <\/span>30\u03bcg\/ml of gemifloxacin, ciprofloxacin, ofloxacin, and norfloxacin were used. For the zones of inhibition <\/span>assay, 0.2ml of the MICs (7.5, 10, 15, 25 and 30 \u03bcg\/ml) of gemifloxacin against particular bacterium was <\/span>used.<\/span><\/p>

Results:<\/b> The MICs of gemifloxacin were 7.5\u03bcg\/ml for Proteus vulgaris, 10\u03bcg\/ml for Staphylococcus aureus and Enterobacter aerogenes, 15\u03bcg\/ml for E. coli, 20\u03bcg\/ml for Pseudomonas aeruginosa, 25\u03bcg\/ml for <\/span>Klebsiella pneumonia and 30\u03bcg\/ml for Alcaligenes faecalis and Serratia marcescens. The clinical isolates <\/span>were most sensitive to ofloxacin with MICs of 7.5\u03bcg\/ml for Proteus vulgaris and 10\u03bcg\/ml for the other <\/span>isolates. The isolates were least susceptible to norfloxacin with MICs of 10\u03bcg\/ml for Proteus vulgaris and <\/span>30\u03bcg\/ml for the other isolates. <\/span>The results show that the clinical isolates were most sensitive to ofloxacin followed by gemifloxacin, <\/span>ciprofloxacin and norfloxacin respectively.<\/span><\/p>

Conclusion<\/b>: Although gemifloxacin is not currently strongly recommended for urinary tract infections, this study has shown that it possesses antibacterial activity against the clinical isolates obtained from urine <\/span>samples of patients with urinary tract infections and could have a place in the treatment of urinary tract <\/span>infections caused by the organisms.<\/span><\/p>

Key words<\/b>: Gemifloxacin, urinary tract infections, invitro activity.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tDownload <\/span>\n\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Invitro activity of gemifloxacin against some clinical bacterial isolates\u00a0of urinary tract infections \u00a0 Ching, Fidelis Poh* , Josephs, Godwin Chimechefulam and Ossai, Awele Maureen \u00a0 *1 Department of Pharmacology, Faculty of Basic Medical Sciences, College of Health Sciences, Niger Delta\u00a0University, Wilberforce Island, Yenagoa, Bayelsa State, Nigeria. E-mail: fidelching@yahoo.ca \u00a0 2\u00a0Department of Pharmaceutical Microbiology, Faculty of […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[237],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts\/5282"}],"collection":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/comments?post=5282"}],"version-history":[{"count":4,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts\/5282\/revisions"}],"predecessor-version":[{"id":5288,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/posts\/5282\/revisions\/5288"}],"wp:attachment":[{"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/media?parent=5282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/categories?post=5282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wapcpharm.org\/journal\/wp-json\/wp\/v2\/tags?post=5282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}